Related Experiment Videos
Neuroprotection for ischaemic stroke: an unattainable goal?
1Comprehensive Stroke Center and Department of Neurology, University of Pennsylvania, Philadelphia 19104-4283, USA. davidliebeskind@yahoo.com
Abstract:
Neuroprotective therapies for acute ischaemic stroke have yet to be realised despite the determined efforts of basic science and clinical investigators. Progressive elucidation of the complex pathophysiology involved in the ischaemic cascade has led to the development of numerous candidate interventions. Preliminary efficacy in animal models has repeatedly resulted in frustration after extensive clinical testing. Failure in the translation of results from animal models to humans implicates potential limitations of the current drug development process. Reflection on prior studies suggests possible flaws at several stages. Incorporation of standardised guidelines for preclinical testing of putative neuroprotective therapies and modification of clinical trial design, methodology and reporting may improve chances for success. The future of neuroprotection for stroke remains bright in spite of previous disappointments.
Insights
Developing effective neuroprotective therapies for acute ischemic stroke remains challenging. Improving preclinical testing and clinical trial design is crucial for future success in stroke neuroprotection research.
Area of Science:
- Neurology
- Translational Medicine
- Pharmacology
Background:
- Acute ischemic stroke presents a significant unmet medical need.
- Despite extensive research, neuroprotective therapies have not yet translated successfully into clinical practice.
- The complex pathophysiology of the ischemic cascade has been progressively elucidated.
Purpose of the Study:
- To analyze the reasons for the failure of neuroprotective therapies in clinical trials for acute ischemic stroke.
- To identify potential improvements in the drug development process for neuroprotection.
- To discuss future directions for stroke neuroprotection research.
Main Methods:
- Review of existing literature on neuroprotective therapies for ischemic stroke.
- Analysis of preclinical animal models and subsequent clinical trial outcomes.
- Critical evaluation of current drug development and clinical trial methodologies.
Main Results:
- Numerous candidate neuroprotective interventions have shown preliminary efficacy in animal models.
- Clinical testing has repeatedly failed to demonstrate efficacy, leading to frustration.
- Limitations in the current drug development process are implicated in the lack of translation.
Conclusions:
- Standardized guidelines for preclinical testing are needed.
- Modifications in clinical trial design, methodology, and reporting are essential.
- Despite past disappointments, the future of stroke neuroprotection remains promising with improved strategies.